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Abstract
Background: Diabetic patients are at increased risk for bacterial infections; these studies provide new insight into
the role of the host defense complement system in controlling bacterial pathogens in hyperglycemic
environments.
Methods: The interactions of complement C3 with bacteria in elevated glucose were assayed for complement
activation to opsonic forms, phagocytosis and bacterial killing. C3 was analyzed in euglycemic and hyperglycemic
conditions by mass spectrometry to measure glycation and structural differences.
Results: Elevated glucose inhibited S. aureus activation of C3 and deposition of C3b and iC3b on the bacterial
surface. S. aureus-generated C5a and serum-mediated phagocytosis by neutrophils were both decreased in
elevated glucose conditions. Interestingly, elevated glucose increased the binding of unactivated C3 to S. aureus,
which was reversible on return to normal glucose concentrations. In a model of polymicrobial infection, S. aureus
in elevated glucose conditions depleted C3 from serum resulting in decreased complement-mediated killing of E.
coli. To investigate the effect of differing glucose concentration on C3 structure and glycation, purified C3
incubated with varying glucose concentrations was analyzed by mass spectrometry. Glycation was limited to the
same three lysine residues in both euglycemic and hyperglycemic conditions over one hour, thus glycation could
not account for observed changes between glucose conditions. However, surface labeling of C3 with sulfo-NHS-
biotin showed significant changes in the surface availability of seven lysine residues in response to increasing
glucose concentrations. These results suggest that the tertiary structure of C3 changes in response to
hyperglycemic conditions leading to an altered interaction of C3 with bacterial pathogens.
Conclusions: These results demonstrate that hyperglycemic conditions inhibit C3-mediated complement effectors
important in the immunological control of S. aureus. Mass spectrometric analysis reveals that the glycation state of
C3 is the same regardless of glucose concentration over a one-hour time period. However, in conditions of
elevated glucose C3 appears to undergo structural changes.
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Background
It has long been recognized that bacterial infections are
more common in diabetic patients, especially S. aureus
diabetic foot infections [1-3], but also more invasive
infections like S. aureus endocarditis [4-6]. Limb-threa-
tening infections are frequently polymicrobial with
enteric Gram-negative bacteria and S. aureus present
[7-9]. In 2004, diabetics underwent 71,000 non-
traumatic limb amputations (American Diabetes Associa-
tion). In acute settings, hyperglycemia has been associated
with increased risk for bacteremia [10] and increased risk
of death from S. aureus bacteremia [11]. Understanding
how pathogenic bacteria interact with critical host
defenses in diabetes is a necessary prerequisite for the
development of future prevention and treatment
strategies.
The human complement system is a major component
of innate immunity and plays a vital role in the control
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[13-15]. C3 is the central component of the complement
system and its activation to C3b is critical for bacterial
opsonization and subsequent phagocytosis, generation of
the anaphylatoxin C5a [16], and terminal complement
cascade activation leading to membrane attack com-
plexes (MAC) that can lyse Gram-negative bacteria [17].
Normal C3 levels in human serum is typically about 1
mg/ml [18].
The impact of hyperglycemia on the complement sys-
tem remains unclear. Diabetic patients are reported to
have elevated levels of circulating C3 and C4, yet
decreased ability to fix complement by IgG [19], suggest-
ing impaired classical pathway activation. In an animal
model of diabetes using non-obese diabetic (NOD) mice,
hyperglycemia resulted in chronic S. aureus hindpaw
infection and decreased killing of S. aureus in a whole-
blood assay [20]. However, the role of complement was
difficult to assess because the mice were C5-deficient and
the whole blood-killing assays used heparin, which inhi-
bits complement activation [21]. C3 has been reported to
be slowly susceptible to glycation with only 20% glycation
after 48 hours in a hyperglycemic environment [22]. It
has also been shown that glucose can bind the biochemi-
cally active (thioester) site of C3 resulting in decreased
attachment to the surface of microbes [23]. For this to
occur however, activation of C3 by the alternative path-
way was necessary to expose the reactive thioester
[24,25]. It has also been postulated that S. aureus may
improve the survival and pathogenicity of other organ-
isms in polymicrobial infections in diabetes [26].
To our knowledge, published data do not exist with
regards to the concentrations of complement proteins
or complement activity in diabetic wounds. Blister fluid
generated by burn injury have C3 levels decreased
approximately two-thirds compared with serum [27].
Additionally, diabetic microvascular disease diminishes
blood flow [28], potentially limiting C3 delivery to dia-
betic extremities. It is unknown to what extent C3
might be generated locally by macrophages [29] in dia-
betic wounds. Very limited data suggest that glucose
levels in diabetic foot ulcers are decreased 6% compared
with arterial levels [30].
The experiments below investigate the functional
interaction between complement C3 and pathogenic
bacteria in elevated glucose, focusing on S. aureus.
Additionally, we utilize mass spectrometry to analyze
the glycation and tertiary structure of C3 in euglycemic
and hyperglycemic environments. In summary, elevated
glucose inhibits the normal activation of C3 on the sur-
face of S. aureus. Hyperglycemic conditions do not
rapidly alter glycation of C3, but does appear to alter
the tertiary structure.
Methods
Ethics Statement
Human blood was obtained from healthy volunteers for
generating serum used as a reagent in these studies.
Eastern Virginia Medical School IRB approved this
study protocol: 02-06-EX-0216. Written informed con-
sent was provided by study participants.
Bacteria and growth
S. aureus strain Reynolds was grown in 2%NaCl Colum-
bia broth at 37°C to stationary-phase growth [31], unless
otherwise noted. A sortase-deficient isogenic mutant
[32] was tested against strain Newman. Clinical isolates
were obtained as discarded de-identified isolates (EVMS
IRB 06-04-WC-0040) - speciation by CLSI criteria [33].
Three isolates were tested for each species: E. coli,
E. cloacae, K. pneumoniae, P. aeruginosa, and S. marces-
cens. PFGE analysis confirmed non-identical strains.
Buffers serum and complement components
PBS was supplemented with glucose (D-(+)-Dextrose
D9434 Sigma). Glucose concentrations were tested in
ranges consistent with euglycemia (3 - 6 mmol/l) [34]
and moderate hyperglycemia (10-17 mmol/l) [35].
Complement activation was stopped with EDTA-GVBS
-
buffer (veronal-buffered saline [VBS] with 0.1% gelatin
and 0.01 M EDTA) [31]. Normal human serum (NHS)
was prepared from human blood and pooled, as pre-
viously described [31]. Purified C3, C3b, and iC3b were
purchased (CompTech) and tested for purity and func-
tionality [36].
Incubation of S. aureus with C3 or serum in glucose
Washed bacteria (1 × 10
9) were combined with purified
C3 (1 μg), C3b, or NHS in 100 μL of PBS/glucose and
incubated for 1 hour at 37°C, unless otherwise noted.
NHS percentage and glucose concentrations used are
shown in each figure. Washed bacteria were stripped of
C3fragments using methylamine, as previously described
[31]. These amounts of bacteria are consistent with
those commonly found in established S. aureus infec-
tions [37].
Assays for C3-fragments and C5a
Bound C3 was quantitated by total C3 ELISA. Flat-
bottom Immunlon-2 plates were coated with goat anti-
human C3 antibody (Complement Technology) at 76
ug/ml in a carbonate buffer overnight at 4°C. Plates
were washed three times with PBST (PBS with 0.1%
Tween-20) and blocked with 3% BSA/PBST for 2 hours
at room temperature. Next, plates were incubated with
test samples or pure C3 for use as a standard curve for
1 hour diluted in block buffer. Plates were washed as
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C3 antibody at a 1:25000 dilution (Sigma) for 1 hour at
room temperature. Finally, plates were washed again
and incubated with a goat anti-chicken HRP antibody at
1:1000 for 1 hour at room temperature. Plates were
developed with TMB Substrate Solution (Thermo Scien-
tific) and stopped with 2.5 N H2SO4. C3-fragments ana-
lyzed by Western blot were probed with antibody that
recognizes the peptide chains of C3, C3b and iC3b, as
previously described [38]. NHS in PBS/glucose was
incubated with 1 × 10
9 S. aureus for 1 hour at 37°C,
sedimented, and measured for C5a using a C5a ELISA
kit (R&D Systems). C3a dot-blot quantitation was per-
formed by titrating pure C3a (Complement Technology)
and samples onto PVDF. The membrane was blocked
with 3% BSA/TBS Tween, probed with rabbit anti-C3a
antibody (Complement Technology), washed, incubated
with horseradish peroxidase-labeled anti-rabbit antibody
(Sigma), washed, and followed by ECL. Optical densito-
metry measurements of the dots provided grey scale
values from which a standard curve was generated and
samples were quantitated by linear regression.
Phagocytosis
Neutrophils were purified from human blood, as pre-
viously described [39]. An aliquot of 1 × 10
9 S. aureus,
log-phase, was incubated in 5% NHS in PBS/glucose
and incubated for 15 min. at 37°C. An aliquot of bac-
teria/serum suspension was incubated with neutrophils
in HBSS (20:1, bacteria: neutrophil), decreasing the final
concentration of glucose to 0.3 mmol/l, and tumbled for
45 min. at 37°C. Samples were fixed by cytospin, stained
with acridine orange, quenched with crystal violet, and
analyzed as previously described [39].
Serum complement-mediated killing
2% NHS/PBS supplemented with glucose was incubated
with 10
9 S. aureus for 1 hour at 37°C, then sedimented
and the supernatant was sterile filtered. A serum-sensi-
tive E. coli isolate was grown to log phase and washed.
In a microtiter plate, 100 μlo ft h eS. aureus-treated
supernatant containing 2% NHS was combined with 10
4
E. coli and incubated for 3 hours at 37°C. Control sam-
ples were processed identically, but without serum. Bac-
teria were quantitated by colony counting.
Mass spectrometry analysis of C3
Purified C3 (0.4 mg/ml) was incubated in PBS with con-
centrations of glucose (0, 3 mM, 6 mM, 10 mM, or 17
mM) for 1 hour at 37°C. The samples were then bioti-
nylated using the EZ-Link Sulfo-NHS-Biotin kit (Pierce,
Rockford, IL) at a molar ratio of 10 biotins per lysine
residue of C3. Excess biotin was removed by spin col-
umn and samples were separated by SDS-PAGE. C3 gel
bands were excised and digested with trypsin and the
extracted peptides were analyzed by ESI-LC MS/MS in
a LTQ linear ion trap (Thermo Fisher) mass spectro-
meter using data dependent acquisition and dynamic
exclusion, similar as described previously [40]. Normal-
ized peptide extracts were automatically loaded on a
CapTrap column (TR1/25109/32 C18; Michrom Biore-
sources Inc) via an autosampler, followed by chromato-
graphic separation under the following conditions:
Solvent A (0.1% formic acid, 0.005% HFBA) and Solvent
B (95% acetonitrile in 0.1% formic acid, 0.005% HFBA).
The tryptic digests were eluted at 500 nl/min with Pico-
Frit columns (75 μm inner diameter, 2 μM tip opening,
New Objective, Woburn, MA) slurry-packed in house
with 10 cm of reverse phase 5 μm1 0 0A n g s t r o mM a g i c
C18 resin (Michrom Bioresources, Auburn, CA). The
acquisition cycle consisted of a survey MS scan with a
set mass range from 350 m/z to 1800 m/z at the highest
resolving power, followed by 5 data-dependent MS/MS
scans using collision dissociation fragmentation (CID)
method assisted with helium gas. Dynamic exclusion
was used with the following parameters: exclusion size
50, repeat count 3, repeat duration 120 s, exclusion time
180 s, exclusion window ± 0.8 Da. Target values were
s e ta t5×1 0
5 and 10
4 for the survey and Tandem MS
scans, respectively, and the maximum ion accumulation
times were set at 200 ms in both cases. Regular scans
were used both for the precursor and tandem MS with
no averaging. In total, 15 MS runs were performed with
extensive blanks between each sample to avoid carry-
over of peptides that could bias quantification. Peak lists
were generated using XCalibur (version 2.1). Sequence
analysis was performed with MASCOT (version 2.2.03)
using SwissProt 2010 × (SwissProt 57.1) database with a
human taxonomy filter enabled that contained 516, 603
sequences entries. The database searches were per-
formed with fixed modification as carbamidomethyl (C)
and variable modifications as oxidation (M), deamida-
tion (N, D) phosphorylation (STY) and biotin labeled
(K). Enzyme specificity was selected to trypsin with 2
missed cleavage sites. The mass tolerance was set at 0.8
Da for both precursor ions and fragment ions. Thresh-
old score for acceptance of individual spectra was set at
0.05. All the MS/MS spectra were manually inspected to
verify the validity of the database search results. False
discovery rates were estimated to be 0.25% on the pro-
tein level by searching a decoy version of the SwissProt
protein database.
Relative protein quantitation was achieved by compar-
ing the number of MS/MS spectra for the same protein
between the three MS/MS analyses for each sample. An
increase in protein abundance is directly related to the
number of proteolytic peptides. An increase in the num-
ber (or abundance) of peptides increases the number of
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spectral counts and relative protein abundance (R
2 =
0.9997) over 2 orders of magnitude [41]. Quantitation
via spectral counting shows strong correlation with iso-
topic label based approaches such as
14N/
15N [42] and
precursor peak area intensity measurements [43]. Spec-
tral count based quantitation has been widely applied
across a diverse set of media [44]. In the current ana-
lyses, biotinylation of lysine residues in C3 after expo-
sure to increasing concentrations of glucose was
determined by spectral counting as follows. The sulfo-
NHS-biotin derivative reacts with the epsilon amino
group of lysine residues thereby increasing the mass of
the modified lysine residues by 226 Da. Glycated lysines
were identified by the increase in mass of 162 Da due to
the addition of a hexose molecule.
Scaffold (Proteome Software, Portland, Oregon, USA)
was used to validate protein identifications derived from
MS/MS sequencing results. Scaffold verifies peptide
identifications assigned by Mascot using the X! Tandem
database search program. Scaffold then probabilistically
validates these peptide identifications using PeptidePro-
phet and derives corresponding protein probabilities
using ProteinProphet. The relative abundance of biotin
modified lysine residues/peptides was obtained by spec-
tral counting using Scaffold Q software. Scaffold nor-
malizes these data by averaging the spectrum counts for
all of the bio-samples and then multiplying the spec-
trum counts in each sample by the average divided by
the individual sample’s sum [45].
Statistical analysis
Means and standard errors were calculated from inde-
pendent experiments (Microsoft Excel XP). Statistical
comparisons were made using Student t test (Instat
GraphPad). Linear regression analyses (InStat GraphPad)
were performed for spectral counts relative to glucose
concentration.
C3 structural models
Three-dimensional drawings of C3 was generated using
PyMOL software http://www.pymol.org based on the
reported crystallographic structure of C3 [46].
Results
Glucose inhibition of C3-mediated opsonophagocytosis of
S. aureus
In order to test whether hyperglycemic conditions
altered C3 activation and binding of activated C3-frag-
ments (C3b and iC3b) on the S. aureus surface, we per-
formed Western blot analysis of C3-fragments stripped
from S. aureus incubated in serum in euglycemic, 3
mmol/l dextrose, and hyperglycemic, 17 mmol/l dex-
trose, conditions (Figure 1A). In each serum
concentration tested, more C3 beta-chain was present
for the 17 mmol/l glucose condition compared with the
3 mmol/l glucose condition, suggesting that more C3
was binding to the S. aureus surface in elevated glucose
over 1 hour. However, for the 17 mmol/l condition
most of the C3 alpha-chain appears to be intact (114
kDa) [29] and uncleaved suggesting that most of the C3
binding S. aureus in elevated glucose is not being acti-
vated to C3b. As expected, in normal glucose conditions
(3 mmol/l glucose), C3 is activated efficiently with mini-
mal or no intact C3 alpha-chain present, resulting in the
104 kDa a’ fragment (C3b) and the 42 kDa a’2( i C 3 b )
bound to the S. aureus surface. We then performed
optical densitometry on Western blots from multiple
independent experiments in 10% NHS in both glucose
conditions (Figure 1B). C3 alpha-chain densitometry was
normalized to the invariant beta-chain, as previously
described [47]. In 3 mmol/l glucose only C3b (35%) and
iC3b (65%) were bound to the S. aureus surface with no
intact C3 identifiable. In 17 mmol/l intact C3 was most
prevalent (59%) compared with C3b (20%) and iC3b
(21%) (P = 0.002). In order to further test whether C3
activation by S. aureus was altered in elevated glucose
we measured C3a generation by dot-blot analysis for
varying concentrations of serum (Figure 1C). C3a gen-
eration was increased in 3 mmol/l glucose compared
with 17 mM glucose by 2-fold (P = 0.01) in 10% NHS
and 3-fold (P = 0.01) in 2% NHS. In order to evaluate
for the possibility of C3(H2O) being generated in hyper-
glycemic conditions, we tested whether C3 in 3 or 17
mmol/L glucose would be cleaved by the presence of
purified factors H and I. C3 remained intact in condi-
tions that efficiently cleaved C3b to iC3b suggesting that
hyperglycemia was not generating C3(H2O) (Figure 1D).
These findings suggested that C3 activation on the S.
aureus surface was inhibited in elevated glucose thereby
limiting deposition of C3b/iC3b opsonins.
Limited generation of C3b on the S. aureus surface
would be expected to decrease the formation of C5-con-
vertases and generation of the potent anaphylatoxin C5a
[29]. S. aureus was incubated in serum in PBS/glucose
and C5a generation was measured by ELISA (Figure
1E). In 17 mmol/l glucose, C5a generation was
decreased 5-fold (P = 0.04) in 1% NHS and decreased 2-
fold (P < 0.01) in 5% NHS. This suggested that elevated
glucose inhibited serum complement activation by S.
aureus which decreased anaphylatoxin generation, likely
resulting from decreased activation of C3 on the staphy-
lococcal surface.
Decreased deposition of C3b/iC3b on S. aureus and
decreased generation of C5a in the presence of elevated
glucose suggested that phagocytosis would also be inhib-
ited. Thus, S. aureus were incubated in 5% NHS for 15
minutes in PBS/glucose. A sample of this bacteria/
Hair et al. Journal of Translational Medicine 2012, 10:35
http://www.translational-medicine.com/content/10/1/35
Page 4 of 16Figure 1 C3-mediated opsonophagocytosis of S. aureus in elevated glucose.( A) C3 binding to S. aureus in 2%, 5%, or 10% NHS in PBS with
3 mmol/l glucose or 17 mmol/l glucose assayed by Western blot. (B) Optical densitometry measurements of the forms of C3 (C3, black bars; C3b,
grey bars; iC3b, white bars) present on the S. aureus surface in 10% NHS for 3 mM or 17 mM glucose. Alpha-chain densitometry was normalized to
the beta-chain and shown as a total percent of C3 forms. Data are mean ± SE for 4 independent experiments. (C) C3a generation by S. aureus in
varying serum and glucose concentrations (3 mmol/l, grey bars and 17 mmol/l, black bars) was assayed by dot blot. Data are mean ± SE for 3
independent experiments. (D) Purified C3 incubated with purified factor H (fH) and factor I (fI) shows no significant cleavage in 3 or 17 mmol/l
glucose, whereas expected cleavage occurs for purified C3b in these conditions. (E) For S. aureus incubated in various concentration of NHS, C5a
generation was increased in 3 mmol/l glucose (grey bars) compared with 17 mmol/l glucose (black bars). Data are mean ± SE for 4 independent
experiments. (F, G) S. aureus opsonized in 5% NHS in 3 mmol/l glucose (grey bars) showed increased phagocytosis by human neutrophils
compared with bacteria opsonized in 17 mmol/l glucose (black bars). The number of bacteria phagocytized by 100 PMN and the number of
neutrophils phagocytizing bacteria were counted by fluorescence microscopy. Data are mean ± SE for 3 independent experiments.
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neutrophils, diluting the concentration of glucose to 0.3
mmol/l, and incubated for 45 minutes. The number of
S. aureus phagocytized after opsonization in 17 mmol/l
glucose was decreased by 2-fold (P < 0.01) compared
with 3 mmol/l glucose (Figure 1F) and the number of
neutrophils phagocytizing bacteria was likewise
decreased (P < 0.01) in 17 mmol/l glucose (Figure 1G).
The concentration of glucose was diluted upon addition
of bacteria to neutrophils to minimize glucose effects on
neutrophil function. It is possible, however, that decreas-
ing the glucose concentration could have increased
complement activation during incubation with neutro-
phils resulting in diminished differences in phagocytosis
efficiency. Nonetheless, these results suggest that ele-
vated glucose inhibited complement-mediated opsono-
phagocytosis of S. aureus.
Glucose concentration affects C3 binding to S. aureus
without C3-convertase formation
Initial Western blot analysis suggested that intact C3,
without activation to C3b, was binding to S. aureus in
elevated glucose conditions. In order to evaluate
whether C3 binding could be replicated in the absence
of other complement components, thus preventing con-
vertase formation, we measured purified C3 binding to
S. aureus.B a c t e r i aw e r ei n c u b a t e df o r1h o u ri nP B S /
glucose with purified C3 (10 μg/ml). C3 was stripped
from washed bacteria and measured by ELISA (Figure
2A). In elevated glucose (17 mmol/l), C3 binding to S.
aureus increased 6fold (P < 0.01) compared with 3
mmol/l glucose. C3 binding rapidly increased above 5
mmol/l and reached saturation at 13 - 17 mmol/l
(Figure 2B). Similar binding studies were performed
with purified C3 and S. aureus in GVBS
++ and VBS
buffers with similar results (data not shown). In order to
evaluate serum C3 binding, but still prevent comple-
ment activation, bacteria were incubated with 0.5% NHS
in EDTA-GVBS
--buffer supplemented with glucose
(Figure 2C). In the presence of elevated glucose (17
mmol/l), serum C3 binding increased 12-fold (P =
0.049) compared with 6 mmol/l glucose. In order to test
the contribution of anti-staphylococcal antibodies, we
depleted these antibodies from serum under comple-
ment preserving conditions, as previously described [38].
The binding of intact C3 to S. aureus in hyperglycemic
conditions was the same for specific antibody-depleted
serum compared with NHS (data not shown). Overall,
greatly increased C3 binding to S. aureus is found in
elevated glucose concentrations similar to what would
be found in moderate hyperglycemia (10-17 mmol/l)
[35] as compared to euglycemia (3 - 6 mmol/l).
In order to exclude the possibility of spontaneous
non-convertase-dependent C3 activation, we tested the
binding of purified C3b to S. aureus (Figure 2D).
Purified C3b is no longer capable of activation and can-
not form covalent bonds. Bound C3b increased 14-fold
for 17 mmol/l glucose compared with 3 mmol/l glucose
(P = 0.025). Western blot analysis confirmed minimal
C 3b i n d i n gi n3m m o l / lg l u c o s ea n dt h a ti n t a c tC 3
bound in 17 mmol/l glucose (Figure 2E).
In order to evaluate whether glucose-mediated C3
binding to S. aureus is caused by the high osmolarity
environment, we tested multiple sugars at the same
osmolarities. S. aureus was incubated with purified C3
and galactose, sucrose, and raffinose at 3 mmol/l and 17
mmol/l, but C3 binding remained unchanged (Figure
2F), suggesting a mechanism other than osmolarity.
In order to evaluate the rapidity of glucose-mediated
C3 binding to S. aureus, we performed time-course
experiments. We also evaluated different phases of
growth as this affects the surface expression for some S.
aureus proteins [48]. S. aureus in stationary or mid-
logarithmic phase was incubated with purified C3 in
PBS at elevated glucose levels (17 mmol/l) for increasing
lengths of time (Figure 2G) and measured for C3 bind-
ing. C3 initially bound more slowly to stationary phase
S. aureus compared with mid-logarithmic phase bac-
t e r i a ,b u tb y6 0m i n u t e st h es a m ea m o u n to fC 3w a s
bound.
Because C3 appears to be binding S. aureus in
elevated glucose without activation and formation of
covalent bonds, we wanted to assess whether glucose-
mediated C3 binding to S. aureus w o u l db er e v e r s e di n
a euglycemic environment. Purified C3 was allowed to
bind to S. aureus in 17 mmol/l glucose, washed in PBS/
glucose (3 mmol/l), and then incubated in PBS/glucose
(3 mmol/l) (Figure 2H). C3 bound to S. aureus
decreased during washing in 3 mmol/l glucose and after
5 minutes the amount of bound C3 decreased a further
3-fold (P = 0.005). This suggested that glucose-mediated
C3 binding to S. aureus is readily reversible upon return
to euglycemic conditions.
C3 binding to clinical S. aureus and Gram-negative
isolates
In order to evaluate whether glucose-meditated C3
binding to S. aureus is a general property of clinical S.
aureus strains, we tested 8 clinical isolates (Figure 3A).
All isolates were recovered from patients with invasive
S. aureus disease; four isolates were methicillin-resistant
(MRSA). Isolates were non-identical by pulse-field gel
electrophoresis. For each isolate, elevated glucose con-
centration increased C3 binding significantly (P ≤ 0.05).
On average, 17 mmol/l glucose increased C3 binding
6-fold (P = 0.001), suggesting that glucose-mediated C3
binding to S. aureus is a general property of clinical
isolates.
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Page 6 of 16Figure 2 Purified and serum C3 binding to S. aureus in varying glucose concentrations.( A, B) Purified C3 (10 μg/ml) binding to S. aureus
in PBS increases at elevated levels of glucose. Data are mean ± SE for 4 independent experiments. (C) C3 binding to S. aureus incubated in 0.5%
NHS in EDTA-GVBS
--buffer, to prevent complement activation, increases at elevated glucose concentrations. Data are mean ± SE for 4
independent experiments. (D) Purified C3b binding to S. aureus in PBS increased at elevated levels of glucose. Purified C3b is incapable of
activation. Data are mean ± SE for 4 independent experiments. (E) C3 bound to S. aureus incubated with purified C3 or 0.5% NHS in PBS was
increased for 17 mmol/l glucose compared with 3 mmol/l. Purified standards for C3 [alpha (114 kDa) and beta (75 kDa) chain and iC3b products
a2
’ (42 kDa)] were included on the gel. (F) Purified C3 binding to S. aureus in PBS did not increase in 17 mmol/l (black bars) compared to 3
mmol/l (gray bars) for galactose, sucrose, or raffinose. Data are mean ± SE for 4 independent experiments. (G) Purified C3 binding to stationary
phase (black circles) or log phase (grey squares) S. aureus in elevated glucose (17 mmol/l) increased over time. Data are mean ± SE for 3
independent experiments. (H) S. aureus bound by C3 in elevated glucose (17 mmol/l) and then incubated in 3 mmol/l glucose shows a rapid
decrease for residual C3 bound to the bacteria. Data are mean ± SE for 3 independent experiments.
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to S. aureus could be mediated by LPXTG-motif
anchored cell-wall proteins. Therefore, we tested a sor-
tase-deficient S. aureus strain [32] and its isogenic parent
strain, Newman (Figure 3B). C3 binding in 17 mmol/l
glucose was the same for both the parental strain and the
sortase-deficient strain, suggesting that LPXTG-motif
cell-wall proteins do not mediate this phenomenon.
In order to evaluate whether glucose-mediated C3
binding occurred for other bacterial species, we tested
15 Gram-negative clinical isolates (Figure 3C). Three
isolates were tested for each of five species. Pulse-field
gel electrophoresis testing demonstrated that strains
were non-identical. Significantly increased C3 binding in
17 mmol/l glucose was found for K. pneumoniae (P =
0.04), but not P. aeruginosa,o rS. marcescens. E. cloacae
(P = 0.07) and E. coli (P = 0.07) strains suggested a
trend towards significance. These results show that
glucose-mediated C3 binding to bacteria also occurs for
at least one Gram-negative species, but is not a general-
ized property for all bacterial species.
C3 depletion from the local environment and
complement killing of E. coli
In light of the dramatic increases in C3 binding to
S. aureus,w es p e c u l a t e dt h a tS. aureus in high glucose
concentrations might deplete C3 from the local environ-
ment. C3-depletion could potentially play an important
role in diabetic wound infections where C3 would likely
be present in limited quantities. S. aureus was incubated
with purified C3 (10 μg/mL) as above, sedimented, and
supernatants measured for residual C3 by ELISA (Figure
4A). In conditions of elevated glucose (17 mmol/l), resi-
dual C3 concentrations decreased 10-fold (P < 0.01)
compared with 3 mmol/l glucose. Using identical condi-
tions, but without S. aureus, no differences in residual
Figure 3 C3 binding to clinical isolates of pathogenic species and mutant S. aureus in elevated glucose.( A) Purified C3 binding to 8
clinical S. aureus isolates was increased in 17 mmol/l glucose (black bars) compared with 3 mmol/l glucose (grey bars). Four strains are MRSA
(MR) and four strains are methicillin-susceptible (SA). Data are mean ± SE for 3 independent experiments for each isolate. Strain Reynolds was
used as a control. (B) Purified C3 binding to a sortase-deficient S. aureus strain (Sortase-) and an isogenic control was similarly increased in 17
mmol/l glucose (black bars) compared with 3 mmol/l glucose (grey bars). Data are mean ± SE for 3 independent experiments. (C) Purified C3
binding to 15 clinical Gram-negative isolates in PBS with 3 mmol/l glucose (grey bars) or 17 mmol/l glucose (black bars). Three isolates were
tested for each species; data are mean ± SE.
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Page 8 of 16C3 concentration were found between any glucose con-
centrations (Figure 4B), showing that the C3 was not
being lost by precipitation or binding to the wall of the
reaction tube.
We then assayed whether C3 would be depleted from
serum incubated with S. aureus in elevated glucose
(Figure 4C). In 10% serum, residual C3 decreased 2-fold
(P = 0.05) for 17 mmol/l glucose compared with 3
Figure 4 C3 depletion by S. aureus in elevated glucose is associated with decreased complement-mediated killing of E. coli.( A)A t
elevated glucose levels, purified C3 is depleted from buffer in the presence S. aureus. Data are mean ± SE for 4 independent experiments. (B)I n
the absence of S. aureus, purified C3 is not depleted from buffer. Data are mean ± SE for 4 independent experiments. (C) S. aureus incubated
with varying concentrations of NHS shows decreased residual C3 in the supernatant for 17 mmol/l glucose (black bars) compared with 3 mmol/l
glucose (grey bars). Data are mean ± SE for 4 independent experiments. (D) For 2% NHS pre-incubated with S. aureus at 3 mmol/l glucose (grey
bars) surviving E. coli decreased > 2 logs compared with 0% NHS. For 2% NHS pre-incubated with S. aureus at 17 mmol/l glucose (black bars)
there was no difference in E. coli survival compared with 0% NHS. Data are mean ± SE for 4 independent experiments. (E) Control experiments
performed without S. aureus in the preincubation step showed similar killing of E. coli at 3 mmol/l glucose (grey bars) or 17 mmol/l glucose
(black bars). Data are mean ± SE for 3 independent experiments.
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Page 9 of 16mmol/l glucose. These results suggest that S. aureus
may deplete C3 in local environments where C3 is pre-
sent in limiting concentrations and glucose concentra-
tion is elevated, such as in diabetic wounds.
Given that C3 can be depleted from the local environ-
ment by S. aureus in elevated glucose, we speculated
that Gram-negative bacteria susceptible to complement-
mediated lysis could incur a survival advantage in poly-
microbial infections. Such an effect could greatly worsen
the disease process in limb-threatening diabetic wound
infections in which S. aureus and Gram-negative bac-
teria are commonly present [8]. S. aureus was incubated
in PBS/glucose ± 2% serum for 1 hour and then
removed from the solution. The serum solutions were
then incubated with a serum-sensitive strain of E. coli
for three hours and plated for colony counting (Figure
4D). In 3 mmol/l glucose, the number of surviving E.
coli in 2% NHS was decreased > 200-fold (P = 0.03)
compared with no serum, typical of complement-
mediated lysis. However, in 17 mmol/l glucose, there
was no difference in the numbers of surviving E. coli
between 2% NHS and the no serum control. These
results suggest that glucose-mediated depletion of C3 by
S. aureus can inhibit complement-mediated lysis of
Gram-negative bacteria improving their survival.
In order to test whether elevated glucose might
prevent complement-mediated lysis of the E. coli,w e
repeated the previous experiments excluding S. aureus
from the pre-incubation step (Figure 4E). This resulted
in similar levels of complement-mediated killing of
E. coli in 17 or 3 mmol/l glucose, suggesting that
elevated glucose did not inhibit complement-mediated
killing of E. coli.
Mass spectrometry analysis of C3 glycation and structure
in elevated glucose
In order to evaluate whether the observed changes in C3
interaction with bacteria could potentially result from
elevated glucose altering the C3 molecule, we used mass
spectrometry-based techniques to evaluate the glycation
and tertiary structure of C3. Purified C3 was incubated
in either 0, 3, 6, 10, or 17 mmol/l glucose for 1 hour in
PBS buffer and then modified by surface biotinylation.
Each of these conditions was repeated in three indepen-
dent experiments. After removal of excess biotin, the C3
molecules were digested to peptides and analyzed by
ESI-LC-MS/MS. Typical peptide map coverage for each
experiment was excellent at ≥ 61% yielding a cumulative
peptide coverage of 88% (Figure 5A). Glycation analysis
was performed for C3 for each glucose concentration,
yet regardless of the glucose concentration tested (3 -
17 mmol/l) lysines K241/K242, K396, and K405/K406
were consistently glycated. Resolution was not sufficient
to differentiate between glycation of K241 and K242 or
K405 and K406. Glycation of a lysine prevents subse-
quent biotinylation. A representative spectrum for the
peptide sequence FLYGKKVEGTAFVIFGIQDGEQR
containing K241/K242 is shown in Figure 5B. The gly-
cated lysines all reside in the C3 beta chain and are
shown superimposed on a structural model of C3 [46]
(Figure 5C). These assays show that C3 is readily gly-
cated at these lysine positions, even in normal glucose
concentrations, and that over this time frame increasing
concentrations of glucose do not alter the glycation pat-
tern. This suggests that glycation is not responsible for
changes in C3 interactions in hyperglycemia.
In order to evaluate whether changes in glucose con-
centration could alter the tertiary structure of C3, we
performed surface modification using sulfo-NHS-biotin.
Lysines on the surface of the molecule are more easily
modified with biotin, whereas internal lysines are less
available for modification. Thus, any alterations in the
tertiary structure of the molecule would result in chan-
ging the availability of specific lysine residues for bioti-
nylation. For the 15 samples tested in this analysis, 41
lysines were identifiable in every sample. Biotinylation
increases the peptide mass by 226 Da which is detected
by MS and the specific modified residue is identified by
MS/MS. A representative spectrum for the fragmenta-
tion and annotation for the C3 peptide sequence
AHEAKIR is shown in Figure 6A. The total sequence
coverage achieved in the MS analysis to identify the
peptides and modified lysine residues was 88%. Most of
the peptides that were not identified in the analyses
have m/z that fall out of the range of the MS instru-
ment used. Spectral count analysis was performed to
quantitate the frequency of biotinylation for each of the
41 lysine residues (Figure 6B). Spectral count analysis
allows for the flexibility of molecules in physiological
conditions in contrast to crystallized molecules which
are static. Sixteen lysines were infrequently labeled with
≤ 5 spectral counts total over 15 samples. These lysine
residues were highly resistant to biotinylation for all
conditions suggesting that they are not available for sur-
face modification. Interestingly, seven lysine residues
showed a statistically significant change in biotinylation
relative to changing glucose concentration, as shown in
Table 1. Increasing glucose concentration correlated
with increasing biotinylation for K405/406, K534, K839,
and K857, but decreasing biotinylation for K82, K1414,
and K1578. The differentially labeled lysines in
the domains of C3 [46] are shown in Figure 6C. The
positions of the changing lysines are shown in three-
dimensional models in Figure 6D. These results strongly
suggest that the tertiary structure of C3 changes as glu-
cose concentration changes and may contribute to alter-
ing the interaction of C3 with bacteria in hyperglycemic
conditions.
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the structure of C3 near the activating cleavage site Arg
726 - Ser 727, we analyzed the mass spectrometry data
using threshold criteria to determine whether biotinyla-
tion of each lysine between regions MG6b and MG6a
was detected for each sample. This approach was used
due to the limited spectral count data available for the
lysines in this region. Biotinylation was detected for
seven lysines in this region, three of which suggested
changes in labeling between euglycemic and hyperglyce-
mic conditions (Table 2 suggesting structural changes
are likely occurring near the activating cleavage site,
which may contribute to decreased C3 activation by
pathogenic bacteria in hyperglycemic conditions.,). Two
of these lysines (K585/586 and K611) were in MG6b
and one (K757) was in MG6a
We had circular dichroism performed by Alliance
Protein Laboratories (Camarillo, CA). Only very slight
differences were noted in the CD patterns for the two
conditions (data not shown). This is likely due to the
relative insensitivity of CD to detect subtle changes in
the tertiary structure of large multi-domain molecules.
Two prior publications show that harsh denaturing con-
ditions are required to induce conformational changes
i nC 3t h a ta r ed e t e c t a b l eb yC D[ 4 9 , 5 0 ] .A n o t h e rp u b l i -
cation suggests circular dichroism is relatively insensitive
Figure 5 Mass spectrometry analysis of C3 glycation in changing glucose.( A) A cumulative peptide map of the fifteen C3 samples
analyzed by ESI-LC-MS/MS showing 88% coverage. Matched peptides are in bold and glycated residues are underlined. (B) A representative
mass spectra of the C3 peptide containing K241/K242 showing glycation and biotinylation. (C) A space filling model of C3 showing the positions
of glycated lysine residues in color.
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Page 11 of 16Figure 6 Mass spectrometry analysis of C3 structure in changing glucose.( A) A representative spectral count analysis of the biotinylation
of the C3 peptide AHEAKIR containing K464. (B) Cumulative spectral counts for biotin surface modification for each of 41 lysine positions. Lysine
residues that showed significant change (P < 0.05) in biotinylation correlating with changing glucose are marked with an asterisk. (C) A linear
peptide map showing the domains of C3 and the relative positions of the lysines that demonstrated changing biotinylation. Lysines that
showed decreased labeling as glucose increased are in italics and lysines that showed increased labeling as glucose increased are underlined.
(D) Model of C3 showing the positions of lysine residues that were increasingly modified as glucose increased (green) and lysine residues that
were decreasingly modified as glucose increased (blue). Other lysine residues are shown in red. 180 degree rotation of model is illustrated to
show all lysines.
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molecules [51]. C3 is both large and complex with 1,641
residues and 13 domains [46].
Discussion
Decreased C3 activation by S. aureus,a sm e a s u r e db y
C3a generation, and decreased deposition of C3b and
iC3b on the bacterial surface in elevated glucose
strongly suggest that, at least in complement limited
environments, hyperglycemic environments inhibit effi-
cient C3-mediated opsonization of S. aureus.A s
expected, diminished deposition of C3b/iC3b resulted in
decreased phagocytosis by neutrophils and decreased
C3b resulted in decreased C5a generation. Since the
normal functioning of neutrophils is already impaired by
elevated glucose [52,53], it is likely that inefficient opso-
nization further retards phagocytosis. Thus, hyperglyce-
mic conditions inhibit efficient complement-mediated
opsonophagocytosis and generation of anaphylatoxin,
likely contributing to diabetic immunocompromise man-
ifested by frequent infections that are difficult to
control.
It is interesting to note that use of continuous insulin
infusion in the intensive care setting in order to rapidly
correct hyperglycemia has been associated with
improved survival [54], which may be due in part to the
elevated risk of bacteremia in hyperglycemia [55]. We
show that the binding of unactivated C3 is rapidly
reversed upon return to euglycemic conditions suggest-
ing that the abnormal interaction of C3 and bacteria can
be reversed upon correction of hyperglycemia. We spec-
ulate that normalization of the interaction of C3 with
bacteria by rapidly reversing hyperglycemia in critical
care settings, where risks of invasive infection are ele-
vated, may contribute to the improved survival.
Another important infectious complication for dia-
betics are polymicrobial limb-threatening infections that
commonly involve S. aureus and Gram-negative bacteria
[7]. Gram-negative bacteria, unlike Gram-positive bac-
teria, are often susceptible to complement-mediated kill-
ing via membrane attack complex formation and lysis.
Given the limited levels of complement proteins likely
to be present in diabetic wounds, we speculated that S.
aureus might be able to further deplete C3 in such an
environment and confer a survival advantage to Gram-
negative organisms. These studies showed that E. coli
killing by complement-mediated lysis was eliminated by
the pre-incubation of serum with S. aureus in 17 mmol/
l glucose. This suggests that glucose-mediated C3
adsorption to S. aureus and depletion from the local
environment can dramatically improve survival of
Gram-negative bacteria from complement-mediated lysis
and may contribute to the pathogenesis of limb-threa-
tening polymicrobial infections.
Prior studies using biochemical methods have sug-
gested that glycation of C3 in high concentrations of
glucose is a very slow process [22], which is inconsistent
with the rapid functional effects found in these studies.
These new mass spectrometry data show that three
lysine sites are glycated by 1 hour, but that the glycation
results were the same regardless of euglycemic or hyper-
glycemic conditions. This is novel data delineating the
sites where C3 is rapidly glycated, K241/K242, K396,
and K405/K406. Since hyperglycemic conditions do not
change the glycation compared with euglycemic condi-
tions over short time frames, glycation is unlikely to
account for the rapid (< 1 hour) changes in interaction
with bacteria in elevated glucose. Prior studies have also
suggested that upon activation by the alternative path-
way, glucose can bind the critical thioester site of C3
[24]; however, our studies suggest that very limited
amounts of C3 is activated on the S. aureus surface in
the presence of elevated glucose. None of the lysines
glycated in our assays reside within the thioester-con-
taining domain (residues 963 - 1268) [46], suggesting
that this was not an important mechanism over short
time intervals.
We speculated that hyperglycemic conditions must
either alter the C3 molecule or a component or
Table 1 Lysine residue spectral counts by dextrose
concentration
Dextrose
Lysine 0 mM 3 mM 6 mM 10 mM 17 mM Total P
K82 6 5 4 2 2 19 0.0264
K405/406 2 2 2 3 4 13 0.0164
K534 2 1 5 6 9 23 0.0242
K839 5 6 6 7 8 32 0.0011
K857 9 12 12 13 15 61 0.0110
K1414 9 8 8 6 6 37 0.0286
K1578 2 2 1 1 0 6 0.0163
Table 2 Number of experiments for which lysine labeling
was detected between C3 regions MG6b and MG6a
Euglycemia Hyperglycemia
Lysine C3
region
3m Ma n d6m M
glucose
10 mM and 17 mM
glucose
K585/
586
MG6b 30
K588 MG6b 45
K593 MG6b 56
K600 MG6b 65
K611 MG6b 02
K700 ANA 6 5
K757 MG6a 03
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change in elevated glucose compared with euglycemic
conditions, we tested whether increasing glucose con-
centration could change the conformation of C3. We
assayed for this possibility by using mass spectrometry-
based surface modification analysis of lysine biotinyla-
tion. Employing spectral count analysis provided quanti-
tative measurement about how frequently a given lysine
site was biotinylated. Of 41 lysines analyzed, over one-
third were highly resistant to surface modification for all
glucose conditions, suggesting that they occupy interna-
lized or protected positions within the C3 molecule.
Seven lysines were shown to undergo significant changes
in surface modification relative to increasing glucose
concentration, suggesting that these regions of the C3
molecule are becoming more or less surface exposed as
glucose changes. The changing availability for surface
modification suggests that the tertiary structure of C3 is
changing in response to changing glucose concentration.
The positions of the lysines with changing modification
are distributed over the molecule suggesting that multi-
ple areas of the molecule are undergoing structural
alteration. These structural changes likely contribute to
the altered interaction of C3 with bacteria in hyperglyce-
mic environments. A recent study showed that high glu-
cose inhibited the lectin pathway by inhibiting
oligosaccharide recognition, but classical and alternative
complement pathway activation were not inhibited in
Weislab ELISA-style complement activation assays [56].
We confirmed in CH50 and AP50 assays that serum
complement-mediated hemolysis was not altered by ele-
vated glucose (data not shown). This suggests that
changes in the structure of C3 likely contribute to the
dramatically altered interaction with pathogenic bacteria,
but are not so great as to globally cripple the ability of
the molecule to function. Together with the rapid rever-
sibility of functional effects upon return to euglycemic
conditions suggests that the structural alterations are
likely to result from non-covalent changes. It also
remains undetermined whether hyperglycemic environ-
ments may alter the surface of pathogenic bacteria, as
has been shown for yeast [57], contributing to the
altered interaction with C3.
Conclusions
The principal finding of our study is that in conditions
of elevated glucose, activation of complement C3 to
functionally active forms (C3b/iC3b) on the S. aureus
surface was inhibited. Curiously, elevated glucose caused
the reversible binding of unactivated C3 to S. aureus.
The limited activation of C3 on the S. aureus surface in
elevated glucose was associated with decreased C5a gen-
eration and decreased phagocytosis. Mass spectrometric
analysis demonstrated that the glycation of C3 was the
same for euglycemic and hyperglycemic conditions over
brief time periods and thus, could not account for the
rapid changes in function. Mass spectrometry-based sur-
face labeling experiments suggested that the tertiary
structure of C3 was altered in the presence of increasing
glucose. Thus, hyperglycemic conditions dramatically
alter the interaction of C3 and pathogenic bacteria in
surprising ways that provide new insight into hypergly-
cemia-mediated immunocompromise contributing to
bacterial infections in diabetic patients.
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